EC Pulmonology and Respiratory Medicine

This short commentary aims at describing some problems of pharmacotherapy, especially with glucocorticoids (GC), in early and late human ontogeny, outlining the necessity of more intense cooperation between health professionals, in order to make more adequate the utilization of pharmacokinetic data in DOHaD paradigm.

Keywords: Glucocorticoids; Ontogeny; Pharmacokinetics

1. Goudochnikov VI., et al. “Pattern of data incompleteness in the manuals and books, recommended as principal sources of pharmacologic information for the students of pharmacy course”. European Journal of Pharmaceutical Science 13 (2001): S31 (Abstract).
2. Goudochnikov VI. “Dynamics of morbidity and mortality for respiratory diseases in three Brazilian states of Southern region”. Jornada Internacional de Enfermagem da Unifra. Santa Maria - RS (2011).
3. Goudochnikov VI. “Central positions of glucocorticoids and stress in the phenomena of hormonal and metabolic programming/imprinting”. Journal of Endocrinological Science1 (2023): 1-7.
4. Goudochnikov VI. “Emerging terms and concepts of pharmacotoxicologic programming/imprinting and embedding, as related to the ontopathogeny of respiratory and other disorders”. EC Pulmonology and Respiratory Medicine6 (2018): 413-415.
5. Goudochnikov VI. “Pharmacotoxicologic mechanisms of phylo- and ontopathogeny: Focusing on stress hormones and proteins”. ARC Journal of Diabetes and Endocrinology1 (2025): 1-3.
6. Goudochnikov VI. “Perinatal treatment of some respiratory disorders with glucocorticoids in relation to prematurity”. EC Pulmonology and Respiratory Medicine1 (2017): 23-27.
7. Goudochnikov VI. “The role of various factors in the ontopathogeny of respiratory disorders: Focusing on glucocorticoids”. EC Pulmonology and Respiratory Medicine9 (2019): 618-620.
8. Goudochnikov VI. “Maturation of prolactin secretion in females: Experimental models help to reveal its probable importance in the intergenerational mode”. Acta Scientific Women’s Health12 (2025): 3-7.
9. Goudochnikov VI. “Use of corticosteroids for the treatment of respiratory and other disorders: Estimating benefit to risk relationship”. Lungs and Breathing Journal3 (2018): 1-3.
10. Goudochnikov VI. “Some properties of inhaled and intranasal corticosteroids: Further detailing in comparison with oral forms”. Lungs and Breathing Journal1 (2019): 1-2.
11. Goudochnikov VI. “Glucocorticoiods and COVID-19: A multifaceted relationship”. EC Pulmonology and Respiratory Medicine1 (2021): 50-52.
12. Goudochnikov VI. “Glucocorticoid-induced growth inhibition: An update”. Open Access Journal of Endocrinology1 (2022): Article 165.
13. Goudochnikov VI. “Treatment with corticosteroids in pediatrics: Advances and problems”. Global Journal of Medical and Biomedical Case Reports1 (2025): Article 023.
14. Goudochnikov VI. “Effects of glucocorticoids on various organs and tissues: Focus on age-related differences”. Endocrinology and Metabolism International Journal 2 (2025): 77-78.
15. Goudochnikov VI. “Toxic stress and corticosteroids in premenopausal period: A case of late embedding?” Acta Scientific Women’s Health2 (2026): 1-2.